Chemoprevention of Prostate Cancer

Journal of Urology

Volumn 182, Issue 2, 2009, Pages 499-508

  Thompson, Ian M ^a   Tangen, Catherine M ^a   Goodman, Phyllis J ^a   Lucia, M Scott ^a   Klein, Eric A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

chemoprevention; dutasteride; finasteride; selenium; vitamin E

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SELENIUM; SELENOMETHIONINE;

ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIGITAL RECTAL EXAMINATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMAN; LIBIDO DISORDER; MALE SEXUAL DYSFUNCTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; RISK ASSESSMENT; RISK REDUCTION; SEXUAL FUNCTION; SIDE EFFECT; SPERMATOZOON DENSITY; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION;

CHEMOPREVENTION; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 67649934982     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.04.015     Document Type: Article

References (54)

1. Eisenberg D.M., Davis R.B., Ettner S.L., et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280 (1998) 1569
2. Seidman H., Mushinski M.H., Gelb S.K., et al. Probabilities of eventually developing or dying of cancer-United States, 1985. CA Cancer J Clin 35 (1985) 36
3. Jemal A., Siegel R., Ward E., et al. Cancer statistics 2008. CA Cancer J Clin 58 (2008) 71
4. Weir H.K., Thun M.U., Hankey B.F., et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 (2003) 1276
5. Sirovich B.E., Schwartz L.M., and Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?. JAMA 289 (2003) 1414
6. Gohagan J.K., Prorok P.C., Hayes R.B., et al. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 21 (2000) 251S
7. Schröder F.H. Screening for prostate cancer (PC)-an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Urol Oncol 26 (2008) 533
8. Clark L.C., Combs Jr. G.F., Turnbull B.W., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276 (1996) 1957
9. Yoshizawa K., Willett W.C., Morris S.J., et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90 (1998) 1219
10. Blot W.J., Li J.Y., Taylor P.R., et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85 (1993) 1482
11. Medina D., and Morrison D.G. Current ideas on selenium as a chemopreventive agent. Pathol Immunopath Res 7 (1988) 187
12. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330 (1994) 1029
13. Pappas A.M. Vitamin E: tocopherols and tocotrienols. Antioxidant Status, Diet, Nutrition, and Health (1998), CRC, Boca Raton, Florida
14. Kristal A.R., Stanford J.L., Cohen J.H., et al. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 8 (1999) 887
15. Dandekar D.S., and Lokeshwar B.L. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin Cancer Res 10 (2004) 8037
16. Smith M.R., Manola J., Kaufman D.S., et al. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy or radiation therapy. J Clin Oncol 24 (2006) 2723
17. Banach-Petrosky W., Ouyang X., Gao H., et al. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin Cancer Res 12 (2006) 5895
18. Beer T.M., Myrthue A., Garzotto M., et al. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiol Biomarkers Prev 13 (2004) 2225
19. Grainger E.M., Schwartz S.J., Wang S., et al. A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen. Nutr Cancer 60 (2008) 145
20. Goetzl M.A., Van Veldhuizen P.J., and Thrasher J.B. Effects of soy phytoestrogens on the prostate. Prostate Cancer Prostatic Dis 10 (2007) 216
21. Hamilton R.J., and Freedland S.J. Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Curr Opin Urol 18 (2008) 333
22. Hoque A., Chen H., and Xu X.C. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 17 (2008) 88
23. Stock D., Groome P.A., and Siemens D.R. Inflammation and prostate cancer: a future target for prevention and therapy?. Urol Clin North Am 35 (2008) 117
24. Jacobs E.J., Rodriguez C., Mondul A.M., et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 97 (2005) 975
25. Price D., Stein B., Sieber P., et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 176 (2006) 965
26. Raghow S., Hooshdaran M.Z., Katiyar S., et al. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62 (2002) 1370
27. Lippman S.M., Klein E.A., Goodman P.J., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301 (2008) 39
28. Duffield-Lillico A.J., Dalkin B.L., Reid M.E., et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91 (2003) 608
29. Albanes D., Heinonen O.P., Huttunen J.K., et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 62 (1995) 1427S
30. Goodman G.E., Schaffer S., Omenn G.S., et al. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 12 (2003) 518
31. Klein E.A., Thompson I.M., Lippman S.M., et al. SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol 166 (2001) 1311
32. Stranges S., Marshall J.R., Natarajan R., et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med 147 (2007) 217
33. Imperato-McGinley J., Gautier T., Zirinsky K., et al. Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol Metab 75 (1992) 1022
34. Thomas L.N., Douglas R.C., Lazier C.B., et al. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 53 (2008) 244
35. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
36. Scardino P.T. The prevention of prostate cancer-the dilemma continues. N Engl J Med 349 (2003) 297
37. Roehrborn C.G. Prevention of prostate cancer with finasteride. N Engl J Med 349 (2003) 1569
38. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239
39. Thompson I.M., Chi C., Ankerst D.P., et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98 (2006) 1128
40. Pepe M.S., Janes H., Longton G., et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159 (2004) 882
41. Thompson I.M., Tangen C.M., Goodman P.J., et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 177 (2007) 1749
42. Thompson I.M., Lucia M.S., Redman M.W., et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol 178 (2007) 107
43. Moinpour C.M., Darke A.K., Donaldson G.W., et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 (2007) 1025
44. Sherbourne C.D. Social functioning: sexual problems measures. In: Stewart A.L., and Ware Jr. J.E. (Eds). Measuring Functioning and Well-Being: The Medical Outcomes Study Approach (1992), Duke University Press, Durham 194-204
45. Lucia M.S., Epstein J.I., Goodman P.J., et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 (2007) 1375
46. Redman M.W., Tangen C.M., Goodman P.J., et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila Pa) 1 (2008) 174
47. Pinsky P., Parnes H., and Ford L. Estimating rates of true high-grade disease in the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila Pa) 1 (2008) 182
48. Shepherd B.E., Redman M.W., and Ankerst D.P. Does finasteride affect the severity of prostate cancer?. A causal sensitivity analysis. J Am Stat Assoc 103 (2008) 1392
49. Cohen Y.C., Liu K.S., Heyden N.L., et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 (2007) 1366
50. Lucia M.S., Darke A.K., Goodman P.J., et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila Pa) 1 (2008) 167
51. Epstein J.I., Sanderson H., Carter H.B., et al. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 66 (2005) 356
52. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (Stage T1c) prostate cancer. JAMA 271 (1994) 368
53. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529
54. Thompson I.M., Tangen C.M., Parnes H.L., et al. Does the level of prostate cancer risk affect cancer prevention with finasteride?. Urology 71 (2008) 854